Lanterne Dx merges with Flagship Biosciences, combining histopathology expertise with computational biology to expand its clinical research service portfolio under a unified brand.
Merger with Flagship Biosciences expands biomarker and digital pathology capabilities, but as a private CRO, there is no direct public market impact.
Acquired by Lanterne Dx, adding computational biology and digital pathology expertise; private company, no direct public market impact.
Lanterne Dx has finalized its merger with Flagship Biosciences to integrate advanced computational biology and digital pathology into its clinical CRO service offerings. The combined entity will continue operations under the Lanterne Dx brand, aiming to bolster biomarker validation capabilities for pharmaceutical and biotech clients.
The merger aims to combine Lanterne Dx's histopathology and biomarker validation services with Flagship Biosciences' computational biology and digital pathology expertise to provide a more comprehensive CRO offering.